This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Thomas Thum, M.D., Ph.D.
CSO and Founder at Cardior Pharmaceuticals


Dr. Thum graduated at Hannover Medical School and initially worked in the field of Molecular Cardiology and Clinical Pharmacology. The current major research focus of Dr. Thum's laboratory is to develop novel diagnostic and therapeutic noncoding RNA-based concepts in cardiovascular medicine. In 2004 he joined the Julius-Maximilians University in Würzburg to finish his training in Internal Medicine and Cardiology. In parallel in 2008 he finished an external PhD program at the National Heart and Lung Institute of the Imperial College in London, U.K. In October 2009 he became Director and Full Professor of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School doing translational research and since 2013 guest professor at the Imperial College London. Since 2021 he is additionally director of the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover, Germany. Dr. Thum is one of the initial pioneers in cardiovascular noncoding RNA research. He also is a founder and current CSO of Cardior Pharmaceuticals GmbH, a clinical stage biotech company developing transformative RNA therapeutics in the cardiovascular space.

Agenda Sessions

  • Transformative RNA Therapeutics for the Treatment of Heart Failure